Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
PYC Therapeutics Limited ( (AU:PYC) ) has shared an announcement.
PYC Therapeutics has issued 2,000,000 unlisted options to director Peter Coleman under an exception to ASX Listing Rule 10.12, with associated terms and conditions and regulatory notices to be filed. The move underscores the company’s use of equity-based incentives in its governance and remuneration framework as it advances its clinical-stage RNA therapeutic programs for genetic diseases.
The most recent analyst rating on (AU:PYC) stock is a Buy with a A$2.85 price target. To see the full list of analyst forecasts on PYC Therapeutics Limited stock, see the AU:PYC Stock Forecast page.
More about PYC Therapeutics Limited
PYC Therapeutics Limited (ASX:PYC) is a clinical-stage biotechnology company focused on developing a new generation of RNA-based precision medicines for patients with genetic diseases who currently lack treatment options. Leveraging a proprietary drug delivery platform to enhance the potency of RNA therapeutics, the company concentrates on monogenic diseases, which are considered to have a higher probability of success in clinical development within the expanding RNA therapeutics market.
Average Trading Volume: 476,660
Technical Sentiment Signal: Strong Buy
Current Market Cap: A$874.9M
For a thorough assessment of PYC stock, go to TipRanks’ Stock Analysis page.